Terns Pharmaceuticals, Inc. TERN NASDAQ

Terns Pharmaceuticals, Inc. (TERN) reported revenue of $0 in its most recent fiscal year. The company reported a net loss of $96M in its most recent fiscal year, with earnings trending at -18.8%/yr. The company has not reported a profit in any of the last 4 years tracked. With a $5B market cap and MOAT composite score of 40/100, the company has a low competitive position.

Criteria proven by this page:

• GROWTH (15/100, Fail) — revenue or earnings are not growing
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 8-year history, the company was profitable in 0 of 8 years — a mixed long-term record
• INCOME (?/100, Fail) — the company is currently operating at a loss
• MOAT (40/100, Fail) — limited competitive moat based on margins and scale

Overall SharesGrow Score: 46/100 with 3/6 criteria passed.